STOCK TITAN

Niagen Bioscience (NAGE) CFO acquires stock through employee purchase plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Niagen Bioscience Chief Financial Officer Pamir Ozan acquired additional company stock as part of compensation. Ozan received 4,255 shares of common stock at $2.71 per share through the Employee Stock Purchase Plan, increasing direct holdings to about 11,627 shares. The filing also shows indirect ownership of about 2,220 shares held by the CFO's spouse.

Positive

  • None.

Negative

  • None.
Insider Pamir Ozan
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Common Stock 4,255 $2.71 $12K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 11,627.159 shares (Direct, null); Common Stock — 2,220.443 shares (Indirect, The reported securities are held by the reporting person's spouse.)
Footnotes (1)
  1. [object Object]
Shares acquired 4,255 shares Common Stock grant/award on June 30, 2026
Acquisition price $2.71 per share Employee Stock Purchase Plan acquisition
Direct holdings after transaction 11,627.159 shares Common Stock held directly by CFO after June 30, 2026
Indirect spousal holdings 2,220.443 shares Common Stock held by CFO’s spouse as of June 30, 2026
Employee Stock Purchase Plan financial
"Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3(c) regulatory
"The acquisition is exempt under Rule 16b-3(c) and 16b-3(d)."
An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.
Rule 16b-3(d) regulatory
"The acquisition is exempt under Rule 16b-3(c) and 16b-3(d)."
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
indirect ownership financial
"The reported securities are held by the reporting person's spouse."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Niagen Bioscience (NAGE) CFO Pamir Ozan report in this Form 4?

Pamir Ozan reported acquiring 4,255 shares of Niagen Bioscience common stock. The shares were obtained through the company’s Employee Stock Purchase Plan at $2.71 per share, reflecting compensation-related ownership rather than an open-market purchase.

How many Niagen Bioscience (NAGE) shares does the CFO directly hold after this transaction?

After the transaction, CFO Pamir Ozan directly holds 11,627.159 shares of Niagen Bioscience common stock. This total includes the 4,255 shares acquired on June 30, 2026 through the Employee Stock Purchase Plan at a price of $2.71 per share.

At what price were the new Niagen Bioscience (NAGE) shares acquired by the CFO?

The 4,255 new shares were acquired at $2.71 per share. These shares were purchased under Niagen Bioscience’s Employee Stock Purchase Plan, making the acquisition a compensation-linked transaction rather than a discretionary open-market stock purchase by the CFO.

What is the nature of the indirect Niagen Bioscience (NAGE) holdings reported by the CFO?

The Form 4 shows 2,220.443 shares of Niagen Bioscience common stock held indirectly. These securities are held by Pamir Ozan’s spouse, as disclosed in the filing, and are therefore reported as indirect ownership rather than shares directly owned by the CFO.

Was the Niagen Bioscience (NAGE) CFO’s share acquisition an open-market purchase?

No, the acquisition was not an open-market purchase. The 4,255 shares were acquired through Niagen Bioscience’s Employee Stock Purchase Plan, a compensation-related program that is exempt under SEC Rules 16b-3(c) and 16b-3(d) for insider transactions.

What SEC rules are referenced in Niagen Bioscience (NAGE) CFO’s Form 4 footnote?

The footnote references SEC Rules 16b-3(c) and 16b-3(d). These rules provide exemptions for certain insider transactions made under issuer plans, such as the Employee Stock Purchase Plan used for the CFO’s 4,255-share acquisition at $2.71 per share.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pamir Ozan

(Last)(First)(Middle)
10900 WILSHIRE BLVD. SUITE 600

(Street)
LOS ANGELES CALIFORNIA 90024

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/30/2026A(1)V4,255A$2.7111,627.159D
Common Stock2,220.443IThe reported securities are held by the reporting person's spouse.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d).
Remarks:
/s/ Jeong James Lee, Attorney-in-Fact07/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)